EP Patent

EP2529742B1 — Pharmaceutical composition comprising dapagliflozin and cyclodextrin

Assigned to Ratiopharm GmbH · Expires 2013-11-20 · 12y expired

What this patent protects

The present invention relates to pharmaceutical compositions comprising dapagliflozin an cyclodextrin, preferably (2-hydroxy)propyl-²-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally,…

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising dapagliflozin an cyclodextrin, preferably (2-hydroxy)propyl-²-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin.

Drugs covered by this patent

Patent Metadata

Patent number
EP2529742B1
Jurisdiction
EP
Classification
—
Expires
2013-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.